PHIO PHARMACEUTICALS CORP. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PHIO PHARMACEUTICALS CORP. (PHIO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $84.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $84.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $21.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $80.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $435.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $84.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $21.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $80.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $435.00K 10-K · filed 2024-04-01 |
| 2021-12-31 | $1.36M 10-K · filed 2023-03-22 |
| 2020-12-31 | $1.37M 10-K · filed 2022-03-22 |
| 2019-12-31 | $1.39M 10-K · filed 2021-03-25 |
| 2018-12-31 | $1.39M 10-K · filed 2020-03-26 |
| 2017-12-31 | $1.34M 10-K · filed 2019-03-27 |
| 2016-12-31 | $1.89M 10-K · filed 2018-03-26 |
| 2015-12-31 | $1.74M 10-K · filed 2017-03-30 |
| 2014-12-31 | $1.39M 10-K · filed 2016-03-30 |
| 2013-12-31 | $861.00K 10-K · filed 2015-03-30 |
| 2012-12-31 | $282.00K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |